Abingdon Health Plc (LSE:ABDX) has spent the past two years reinventing itself from a Covid-era test maker into a contract development and Manufacturing organisation (CDMO) for lateral-flow diagnostics, and the numbers are starting to show it. A trading update on 29 July 2026 reported Revenue for the year to 30 June 2026 of £11.3m, up 31%, and a move into adjusted EBITDA profitability in the second half. Yet the figure fell short of the £12.6m guidance the York-based group had reiterated as recently as March.

That gap frames the question ahead of full results in early October: has Abingdon quietly turned the corner, with a contracted pipeline supporting what management calls "significant revenue growth" in FY27, or does growth remain hostage to the timing of individual customer programmes?

Trading update: revenue up 31%, H2 EBITDA positive, but guidance missed

The 29 July 2026 update covered the year to 30 June 2026. Revenue rose to £11.3m from £8.6m in FY25, with second-half revenue 63% higher than the first half, and the group achieved adjusted EBITDA profitability in H2 as promised in its January and March updates. Cash at 30 June 2026 was £2.9m, up from £1.9m a year earlier but below the £3.7m held at 31 December 2025.

The shortfall against the £12.6m target was attributed partly to roughly £0.5m of reader unit sales that moved to August 2026 at the customer's request. In January the company had already flagged that contracts with Find Out From Home (FOFH) had shifted into FY27 pending that customer's own fundraising.

Executive chairman Dr Chris Hand said revenue growth of "over 30% and a move into adjusted EBITDA profitability in the second half of the year" reflected strong performance, adding that CDMO contracts announced during the year "provide a strong foundation for significant revenue growth in FY27". Audited FY26 results are expected in early October 2026.

The update capped a year of contract wins. On 12 March 2026 Abingdon announced an 18-month, c.US$2.5m contract with a UK-based organisation to develop a clinical self-test, with most revenue falling in FY27. On 30 March 2026 it disclosed contracts worth about £4.8m over 27 months with a US customer for multiplex quantitative lateral-flow systems. And on 11 May 2026 UpFront Diagnostics launched its UKCA-marked LVOne stroke test, manufactured by Abingdon, in a London Ambulance Service pilot across around 280 vehicles.

Business overview: an end-to-end lateral-flow CDMO

Abingdon Health develops, manufactures and provides regulatory and performance-evaluation services for lateral-flow rapid tests, taking a customer's assay from feasibility through validation and regulatory submission into routine manufacture. It earns fees on milestone-based work packages and, ultimately, manufacturing volumes.

The headquarters and main manufacturing site are in York, with Abingdon Analytical in Doncaster providing performance evaluation and IVDeology and CS Lifesciences, both acquired in 2024, providing regulatory consultancy. Abingdon Health USA opened in Madison, Wisconsin, in October 2024 and is adding development and manufacturing capacity; in May 2026 the state awarded it performance-based tax credits of up to $370,000 over three years.

The group also sells its own Abingdon Simply Test self-tests, the AppDx smartphone reader, patented in Europe in December 2025, and seaweed-based test housings developed with SymbioTex. In FY25 regulatory services (£3.4m) and contract development (£3.2m) were the largest revenue lines, followed by contract manufacturing (£1.3m) and product sales (£0.5m). Customers are mainly diagnostics developers in the UK, Europe and North America.

Financial performance: losses narrowing as scale builds

The most recent audited figures cover the year to 30 June 2025, published on 11 November 2025. Revenue rose 40% to £8.6m from £6.1m, but gross Margin fell to 44.3% from 60.0% as the mix shifted towards services. Adjusted EBITDA was a loss of £2.6m (FY24: £1.1m loss), the loss before tax was £3.5m (FY24: £1.4m) and basic loss per share was 0.93p (FY24: 0.42p). Cash at 30 June 2025 was £1.9m against borrowings of £0.7m. No Dividend was declared.

The half-year to 31 December 2025, reported on 17 March 2026, showed revenue up 37% to £4.2m (£4.5m including grant income), with contract development up 75% to £1.4m and regulatory services up 49% to £1.9m. Gross margin slipped to 33.3% from 38.3%. The adjusted EBITDA loss narrowed to £1.7m from £1.9m and the loss before tax to £2.3m from £2.6m, with a loss per share of 0.59p. Cash was £3.7m, helped by the October 2025 placing and retail offer at 6p a share, which raised about £3.2m net and diluted holders by roughly 23%. Full-year FY26 margins and Cash Flow remain unconfirmed until the audited results.

What could drive the stock next?

The first catalyst is the FY26 results in early October 2026, which will show whether H2 adjusted EBITDA profitability translated into operating cash generation, and what FY27 guidance looks like given the deferred reader sales and FOFH programmes.

Second is milestone revenue from contracts already signed, including the £4.8m US multiplex programme, the $2.5m self-test project and the €2m and c.US$2.5m companion-diagnostic wins from mid-2025. Conversion of development work into routine manufacturing, as with LVOne, is where CDMO Economics improve.

Third is the US build-out in Madison, the main use of last year's fundraise, alongside the April 2026 OTCQB Quotation intended to widen the US investor base. For context, the shares were quoted at around 12.5p, valuing the company at about £31m according to lse.co.uk at the time of writing, roughly double the 6p placing price of October 2025.

Risks investors should watch

Revenue timing is the most obvious risk: FY26 missed guidance by about £1.3m because customers deferred orders and programmes, and a Business built on milestone work packages will remain lumpy. Customer concentration follows, with a handful of contracts driving growth and one key customer, FOFH, dependent on its own fundraising.

Profitability is unproven at the full-year level. FY25 lost £3.5m before tax and H1 FY26 lost £2.3m, while gross margin has fallen from 60% to the low-to-mid 30s. Cash of £2.9m at 30 June 2026 is modest for a group expanding a US facility, and the company raised Equity in both August 2024 and October 2025; a further raise cannot be ruled out if cash generation disappoints.

Execution risk in Wisconsin, competition from larger CDMOs, reliance on customers achieving regulatory clearance, and exposure to dollar- and euro-denominated contracts add to the picture.

Outlook

Abingdon Health enters FY27 with a larger contracted base than a year ago, a second half that management says was adjusted-EBITDA positive, and a US operation moving from set-up to manufacturing. The October results will need to confirm that trajectory in audited form and set credible FY27 guidance after a year in which the Top Line fell short. Investors should monitor the timing of deferred FOFH and reader revenue, gross margin recovery, Operating Cash Flow and evidence that development contracts are converting into recurring manufacturing volumes.